	US 12,295,977 B2
	Oncolytic reovirus
Maya Shmulevitz, Edmonton (CA); Adil Mohamed, Edmonton (CA); Mary Hitt, Edmonton (CA); and Wan Kong Yip, Edmonton (CA)
Appl. No. 16/979,458
Filed by The Governors of the University of Alberta, Edmonton (CA)
PCT Filed Mar. 13, 2019, PCT No. PCT/CA2019/050312 § 371(c)(1), (2) Date Sep. 9, 2020, PCT Pub. No. WO2019/173919, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/642,881, filed on Mar. 14, 2018.
Prior Publication US 2021/0008136 A1, Jan. 14, 2021
Int. Cl. A01K 35/00 (2006.01); A61K 35/765 (2015.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/765 (2013.01) [A61P 35/00 (2018.01); A61P 37/02 (2018.01); C12N 7/00 (2013.01); C12N 2720/12221 (2013.01); C12N 2720/12222 (2013.01); C12N 2720/12232 (2013.01)]

12 Claims

1. A T3D^PLreovirus genetically modified to express a T3D^PLreovirus λ2 protein comprising a mutation in a FLAP domain, wherein said mutation comprises a substitution of isoleucine at position 1274 in SEQ ID NO: 9, wherein the substitution is I1274M or I1274M.